Pediatr Surg Int
. 2022 Jul 16.
doi: 10.1007/s00383-022-05176-1. Online ahead of print. https://pubmed.ncbi.nlm.nih.gov/35841395/
Trends in use of prostacyclin analogs for management of CDH-associated pulmonary hypertension
Akila B Ramaraj 1 2, Samuel E Rice-Townsend 3, Carrie L Foster 3, Delphine Yung 4, Emma O Jackson 5, Ashley H Ebanks 6, Rebecca A Stark 3, Congenital Diaphragmatic Hernia Study Group
Affiliations expand
- PMID: 35841395
- DOI: 10.1007/s00383-022-05176-1
Abstract
Purpose: Off-label use of prostacyclins to manage congenital diaphragmatic hernia-associated pulmonary hypertension (CDH-PHTN) has been described over recent years, but use is not standardized across institutions. This study aims to describe trends in use of these medications in the CDH Study Group (CDHSG) patients.
Methods: The CDHSG was queried for all patients born from 2007 to 2019. Records were reviewed to describe the number of patients receiving prostacyclins, the day of life on which the agent was started, start time relative to ECLS, the duration of medication use, and continuation of the medication at the time of discharge. Finally, trends in use by year of birth were evaluated to assess for changes in use over time.
Results: There were 6439 patients identified from the registry who were born during the study period. 4372 (68%) patients received medications to treat pulmonary hypertension. Of these, 604 (14%) received a prostacyclin at some point during their care. The median start time for prostacyclins was 7.5 days of life (mean 16.9 days, SD 32.5 days), and the median duration was 12.5 days (mean 25.1 days, SD 49.1 days). Among patients who received prostacyclins, 340 patients required ECLS during care, 53 (15.5%) of whom started the prostacyclin prior to ECLS, and 159 (46.8%) of whom started prostacyclin therapy during their ECLS run. Only a small cohort (26/604, 4.3%) required continuation of the prostacyclin at the time of discharge. The proportion of patients receiving a prostacyclin remained relatively stable over the study period.
Conclusions: While the proportion of patients receiving a prostacyclin for management of CDH-PHTN has remained relatively stable over the last 13 years, there is significant variation in timing of initiation and duration of use especially in the pre-ECLS period that warrants further investigation to describe optimal use in these patients.
Keywords: CDH; Clinical outcomes; Prostacyclins; Pulmonary hypertension.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
